Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging

Sotirios Chondrogiannis, Maria Cristina Marzola, Adil Al-Nahhas, Thirumalesha D. Venkatanarayana, Alberto Mazza, Giuseppe Opocher, Domenico Rubello

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Dihydroxyphenylalanine (DOPA) is a neutral amino acid that resembles natural L-dopa (dopamine precursor). It enters the catecholamine metabolic pathway of endogenous L-DOPA in the brain and peripheral tissues. It is amenable to labeling with fluorine-18 (F) for PET imaging and was originally used in patients with Parkinson's disease to assess the integrity of the striatal dopaminergic system. The recent introduction and use of hybrid PET/CT scanners has contributed significantly to the management of a series of other pathologies including neuroendocrine tumors, brain tumors, and pancreatic cell hyperplasia. These pathologic entities present an increased activity of L-DOPA decarboxylase and therefore demonstrate high uptake of F-DOPA. Despite these potentially promising applications in several clinical fields, the role of F-DOPA has not been elucidated completely yet because of associated difficulties in synthesis and availability. Unfortunately, the available literature does not provide recommendations for procedures or administered activity, acquisition timing, and premedication with carbidopa. The aim of this paper is to outline the physiological biodistribution and normal variants, including possible pitfalls that may lead to misinterpretations of the scans in various clinical settings.

Original languageEnglish
Pages (from-to)1141-1149
Number of pages9
JournalNuclear Medicine Communications
Volume34
Issue number12
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Dihydroxyphenylalanine
Carbidopa
Neutral Amino Acids
Corpus Striatum
Carboxy-Lyases
Neuroendocrine Tumors
Fluorine
Premedication
Levodopa
Metabolic Networks and Pathways
Brain Neoplasms
Catecholamines
Hyperplasia
Parkinson Disease
Dopamine
Pathology
Brain

Keywords

  • 4-dihydroxyphenylalanine PET/CT
  • F-DOPA
  • F-DOPA pitfalls
  • F-DOPA variants
  • biodistribution
  • L-6-fluoro-3
  • physiologic pattern

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Chondrogiannis, S., Cristina Marzola, M., Al-Nahhas, A., Venkatanarayana, T. D., Mazza, A., Opocher, G., & Rubello, D. (2013). Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nuclear Medicine Communications, 34(12), 1141-1149. https://doi.org/10.1097/MNM.0000000000000008

Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. / Chondrogiannis, Sotirios; Cristina Marzola, Maria; Al-Nahhas, Adil; Venkatanarayana, Thirumalesha D.; Mazza, Alberto; Opocher, Giuseppe; Rubello, Domenico.

In: Nuclear Medicine Communications, Vol. 34, No. 12, 12.2013, p. 1141-1149.

Research output: Contribution to journalArticle

Chondrogiannis, S, Cristina Marzola, M, Al-Nahhas, A, Venkatanarayana, TD, Mazza, A, Opocher, G & Rubello, D 2013, 'Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging', Nuclear Medicine Communications, vol. 34, no. 12, pp. 1141-1149. https://doi.org/10.1097/MNM.0000000000000008
Chondrogiannis S, Cristina Marzola M, Al-Nahhas A, Venkatanarayana TD, Mazza A, Opocher G et al. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nuclear Medicine Communications. 2013 Dec;34(12):1141-1149. https://doi.org/10.1097/MNM.0000000000000008
Chondrogiannis, Sotirios ; Cristina Marzola, Maria ; Al-Nahhas, Adil ; Venkatanarayana, Thirumalesha D. ; Mazza, Alberto ; Opocher, Giuseppe ; Rubello, Domenico. / Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. In: Nuclear Medicine Communications. 2013 ; Vol. 34, No. 12. pp. 1141-1149.
@article{d5f5501d20f7451a917fa73d1149d098,
title = "Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging",
abstract = "Dihydroxyphenylalanine (DOPA) is a neutral amino acid that resembles natural L-dopa (dopamine precursor). It enters the catecholamine metabolic pathway of endogenous L-DOPA in the brain and peripheral tissues. It is amenable to labeling with fluorine-18 (F) for PET imaging and was originally used in patients with Parkinson's disease to assess the integrity of the striatal dopaminergic system. The recent introduction and use of hybrid PET/CT scanners has contributed significantly to the management of a series of other pathologies including neuroendocrine tumors, brain tumors, and pancreatic cell hyperplasia. These pathologic entities present an increased activity of L-DOPA decarboxylase and therefore demonstrate high uptake of F-DOPA. Despite these potentially promising applications in several clinical fields, the role of F-DOPA has not been elucidated completely yet because of associated difficulties in synthesis and availability. Unfortunately, the available literature does not provide recommendations for procedures or administered activity, acquisition timing, and premedication with carbidopa. The aim of this paper is to outline the physiological biodistribution and normal variants, including possible pitfalls that may lead to misinterpretations of the scans in various clinical settings.",
keywords = "4-dihydroxyphenylalanine PET/CT, F-DOPA, F-DOPA pitfalls, F-DOPA variants, biodistribution, L-6-fluoro-3, physiologic pattern",
author = "Sotirios Chondrogiannis and {Cristina Marzola}, Maria and Adil Al-Nahhas and Venkatanarayana, {Thirumalesha D.} and Alberto Mazza and Giuseppe Opocher and Domenico Rubello",
year = "2013",
month = "12",
doi = "10.1097/MNM.0000000000000008",
language = "English",
volume = "34",
pages = "1141--1149",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging

AU - Chondrogiannis, Sotirios

AU - Cristina Marzola, Maria

AU - Al-Nahhas, Adil

AU - Venkatanarayana, Thirumalesha D.

AU - Mazza, Alberto

AU - Opocher, Giuseppe

AU - Rubello, Domenico

PY - 2013/12

Y1 - 2013/12

N2 - Dihydroxyphenylalanine (DOPA) is a neutral amino acid that resembles natural L-dopa (dopamine precursor). It enters the catecholamine metabolic pathway of endogenous L-DOPA in the brain and peripheral tissues. It is amenable to labeling with fluorine-18 (F) for PET imaging and was originally used in patients with Parkinson's disease to assess the integrity of the striatal dopaminergic system. The recent introduction and use of hybrid PET/CT scanners has contributed significantly to the management of a series of other pathologies including neuroendocrine tumors, brain tumors, and pancreatic cell hyperplasia. These pathologic entities present an increased activity of L-DOPA decarboxylase and therefore demonstrate high uptake of F-DOPA. Despite these potentially promising applications in several clinical fields, the role of F-DOPA has not been elucidated completely yet because of associated difficulties in synthesis and availability. Unfortunately, the available literature does not provide recommendations for procedures or administered activity, acquisition timing, and premedication with carbidopa. The aim of this paper is to outline the physiological biodistribution and normal variants, including possible pitfalls that may lead to misinterpretations of the scans in various clinical settings.

AB - Dihydroxyphenylalanine (DOPA) is a neutral amino acid that resembles natural L-dopa (dopamine precursor). It enters the catecholamine metabolic pathway of endogenous L-DOPA in the brain and peripheral tissues. It is amenable to labeling with fluorine-18 (F) for PET imaging and was originally used in patients with Parkinson's disease to assess the integrity of the striatal dopaminergic system. The recent introduction and use of hybrid PET/CT scanners has contributed significantly to the management of a series of other pathologies including neuroendocrine tumors, brain tumors, and pancreatic cell hyperplasia. These pathologic entities present an increased activity of L-DOPA decarboxylase and therefore demonstrate high uptake of F-DOPA. Despite these potentially promising applications in several clinical fields, the role of F-DOPA has not been elucidated completely yet because of associated difficulties in synthesis and availability. Unfortunately, the available literature does not provide recommendations for procedures or administered activity, acquisition timing, and premedication with carbidopa. The aim of this paper is to outline the physiological biodistribution and normal variants, including possible pitfalls that may lead to misinterpretations of the scans in various clinical settings.

KW - 4-dihydroxyphenylalanine PET/CT

KW - F-DOPA

KW - F-DOPA pitfalls

KW - F-DOPA variants

KW - biodistribution

KW - L-6-fluoro-3

KW - physiologic pattern

UR - http://www.scopus.com/inward/record.url?scp=84887258844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887258844&partnerID=8YFLogxK

U2 - 10.1097/MNM.0000000000000008

DO - 10.1097/MNM.0000000000000008

M3 - Article

C2 - 24128899

AN - SCOPUS:84887258844

VL - 34

SP - 1141

EP - 1149

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 12

ER -